Pay in 4 interest-free payments of $5.15 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
no refrigeration needed Retatrutide (triple-agonist GLP-1, GIP, glucagon) Status: Currently in Phase II/III trials Average weight loss: 17.524% in initial studies Notable facts: Promising triple-targeting mechanism for substantial weight reduction Mazdutide (IBI-362) Status: Approved in China as of June 2025
Studies have also found that NAC can be useful for people with schizophrenia and manic depression
In this study, we introduce Linker-GPT, a Transformer-based deep learning framework leveraging self-attention mechanisms to generate novel ADC linkers with high structural diversity and synthetic feasibility
As seen below, the change in the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS), reflecting physical limitations and symptoms, nearly doubled
US$ 25.30
US$ 27.00
US$ 24.12
US$ 28.39
